In alignment with its overall strategy of developing PAX2 targeting compounds, Phigenix has expanded its technology to now include a new companion diagnostic test for breast cancer, which involves measuring PAX2 and DEFB1, along with determining the expression status of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). This test was based on our findings that there is a 92% correlation between PAX2 and HER2 expression in breast cancer patients. Phigenix has also demonstrated that PAX2 expression is suppressed by certain therapies such as HER2 antibody drug conjugates, which results in breast cancer cell death. Prescreening for these markers may help physicians determine which patients are more likely to response to these ADC’s, including patients with cancers that are resistant to other therapies such as trastuzumab and taxanes. This test may be a valuable tool for personalized medicine in breast cancer. Phigenix is currently seeking licensing or co-development partnerships for this technology.